News and Announcements
Phylogica Achieves Milestone in Pharma Collaboration
- Published January 31, 2013 2:39PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
PERTH, AUSTRALIA: January 31, 2013 – Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, announced today the extension of its collaboration with Janssen Biotech, Inc. and its affiliates (“Janssen”) to discover, develop and commercialise new classes of peptide-drug conjugates derived from Phylogica’s Phylomer® drug discovery platform. Phylogica has received an undisclosed payment for funding additional research associated with the extension of the collaboration.
To read a full ASX announcement, please download the document below.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
